The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy

Wuhan University500 enrolled

Overview

To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

500

Sex: ALLMin age: 20 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients can take HLJDT Exclusion Criteria: * patients can not take HLJDT

Wuhan University

Wuhan, Hubei, China

RECRUITING

Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang（HLJDT) in maintain therapy

Time frame: 6 months

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.